MedTrace Logo

A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)

NCT07311200 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-04-24

No results posted yet for this study

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.

Conditions

  • Active Systemic Lupus Erythematosus

Interventions

DRUG

D-2570

Participants will be assigned to one of the following groups: Group A, Group B, Group C, or the placebo control group.

DRUG

D-2570 Placebo

D-2570 Placebo

Sponsors & Collaborators

  • InventisBio Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Xiaofeng · Zeng

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-12
Primary Completion
2028-08-31
Completion
2028-12-31

Countries

  • China

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07311200 on ClinicalTrials.gov